## 3 Results
### Primary Part: Individual Patient-Level Data for Patients Initially Diagnosed with Stage I-III NSCLC
#### 3.1.3 Initial Treatments
\begin{table}
\begin{tabular}{c c c c c} \hline  & **Overall (N = 319)** & **Stage I (N = 115)** & **Stage II (N = 98)** & **Stage III (N = 106)** \\ \hline Type of resection, among resected patients \({}^{{\dagger}}\) & & & & \\ Lobectomy & 77.7 (167/215) & 76.6 (72/94) & 81.9 (68/83) & 71.1 (27/38) \\ Segmentectomy & 7.9 (17/215) & 13.8 (13/94) & 3.6 (3/83) & 2.6 (1/38) \\ Wedge resection & 7.4 (16/215) & 9.6 (9/94) & 6.0 (5/83) & 5.3 (2/38) \\ Surgical approach, among resected patients (unknown for n = 4) \({\dagger}\) & & & \\ VATS & 50.7 (107/211) & 71.0 (66/93) & 40.2 (33/82) & 22.2 (8/36) \\ Thoreacotomy & 46.9 (99/211) & 24.7 (23/93) & 58.5 (48/82) & 77.8 (28/36) \\ Surgical Margin, among resected patients (unknown for n = 12) & & & \\ R0 & 95.6 (194/203) & 97.8 (90/92) & 93.4 (71/76) & 94.3 (33/35) \\ R1 & 3.9 (8/203) & 1.1 (1/92) & 6.6 (5/76) & 5.7 (2/35) \\ R2 & 0.5 (1/203) & 1.1 (1/92) & - & \\ Most common reasons for not performing SUR, among unresected patients (unknown for n = 20) \({}^{{\ddagger}}\) & & & \\ Poor cardiorespiratory reserve & 31.9 (23/72) & 38.9 (7/18) & 22.2 (2/9) & 31.1 (14/45) \\ Comorbidity & 29.2 (21/72) & 44.4 (8/18) & 22.2 (2/9) & 24.4 (11/45) \\ Advanced age & 20.8 (15/72) & 16.7 (3/18) & 44.4 (4/9) & 17.8 (8/45) \\ Unresectable disease stage IIIC & 12.5 (9/72) & & & 20.0 (9/45) \\ Patient frailty & 11.1 (8/72) & 5.6 (1/18) & 22.2 (2/9) & 11.1 (5/45) \\ \hline ST (\(\pm\)RT or SUR) & & 7.8 (9/115) & 43.9 (43/98) & 82.1 (87/106) \\ Most common reasons for not receiving ST, among those not receiving ST (unknown for n = 28) \({\ddagger}\) & & & \\ Not indicated & 66.4 (93/140) & 83.9 (7/87) & 43.2 (19/44) & 11.1 (1/9) \\ Patient’s refusal & 9.3 (13/140) & 1.1 (1/87) & 20.5 (9/44) & 33.3 (3/9) \\ Tumor board decision & 7.9 (11/140) & 9.2 (8/87) & 2.3 (1/44) & 22.2 (2/9) \\ \hline RT (\(\pm\)ST or SUR) & & 22.3 (71/319) & 16.5 (19/115) & 14.3 (14/98) & 35.8 (38/106) \\ \hline CRT (\(\pm\)SUR) & & 10.0 (32/319) & - & 1.0 (1/98) & 29.2 (31/106) \\ cCRT, among those receiving CRT & 50.0 (16/32) & - & 100.0 (1/1) & 48.4 (15/31) \\ cCRT, among those receiving CRT & 46.9 (15/32) & - &. & 48.4 (15/31) \\ Both cCRT and cCRT, among those receiving CRT & 3.1 (1/32) & - &. & 3.2 (1/31) \\ \hline
**Time from histological NSCLC confirmation to start of ITS, among patients receiving that treatment, median (IQR)\({}^{{\ddagger}}\)** & & & & \\ \hline Any (non)pharmacologic treatment, days \({}^{{\lx@sectionsign}}\) & 24.0 (7.0–39.0) & 25.5 (0.0–40.0) & 27.0 (7.0–42.0) & 21.5 (12.0–33.0) \\ \hline SUR, days \({}^{{\lx@sectionsign}}\) & 26.0 (0.0–44.0) & 19.0 (0.0–34.0) & 26.0 (2.0–44.0) & 53.0 (21.0–101.0) \\ \hline RT, months & 2.1 (1.3–3.5) & 1.4 (1.2–1.7) & 1.9 (1.0–2.5) & 2.9 (1.7–4.5) \\ \hline ST, months & 1.2 (0.7–2.0) & 2.2 (1.9–2.4) & 2.0 (1.4–2.8) & 0.8 (0.5–1.3) \\ \hline \multicolumn{4}{c}{**Pharmacologic categories and drug classes among patients treated with ST, \% (n/N)**} \\ \hline Chemotherapy & 94.2 (131/139) & 100.0 (9/9) & 97.7 (42/43) & 92.0 (80/87) \\ Platinum compound & 93.5 (130/139) & 100.0 (9/9) & 97.7 (42/43) & 90.8 (79/87) \\ Folic acid analogue & 39.6 (55/139) & 66.7 (6.9) & 37.2 (16/43) & 37.9 (33/87) \\ Vinca alkaloid and analogue & 26.6 (37/139) & 22.2 (2/9) & 46.5 (20/43) & 17.2 (15/87) \\ Taxane & 14.4 (20/139) & 11.1 (1/9) & 21.8 (19/87) \\ Antimetabolite & 13.7 (19/139) & - & 11.6 (5/43) & 16.1 (14/87) \\ Topoisomerase II inhibitor & 1.4 (2/139) & - & 2.3 (1/43) & 1.1 (1/87) \\ \hline ICI & 28.1 (39/139) & - & 4.7 (2/43) & 42.5 (37/87) \\ Anti-PD-1 & 20.9 (29/139) & - & 4.7 (2/43) & 31.0 (27/87) \\ Anti-PD-L1 & 7.2 (10/139) & - & - & 11.5 (10/87) \\ \hline Targeted therapy & 0.7 (1/139) & - & - & 1.1 (1/87) \\ ALK TKI & 0.7 (1/139) & - & - & 1.1 (1/87) \\ \hline \end{tabular}  
* For variables not following a normal distribution in at least one of the study subpopulations, a uniform presentation of median (IQR) was applied. \({}^{{\ddagger}}\) Excluding supportive treatments; \({}^{{\dagger}}\) Other types of resection were reported in \(\leq\)10 patients, each. \({\dagger}\) Other surgical approaches were reported in \(\leq\)2 patients, each. \({\ddagger}\) Reported in \(\geq\)20.0% in any of the examined subpopulations; \({}^{{\ddagger}}\) Impulation of the start of ITS has been implemented for 2 patients due to unknown day and/or month; \({}^{{\lx@sectionsign}}\) Nine patients have performed surgery before the histological confirmation of NSCLC. Abbreviations: ALK, Anapalistic Lymphoma Kinase; cCRT, concurrent CRT; CRT, Chemoradiation; ICI, Immune Checkpoint Inhibitor; IQR, Interquartile Range; ITS, Initial Therapeutic Strategy; N, number of patients with available data; n, number of patients with variable; NSCLC, Non-Small Cell Lung Cancer; PD-L1, Programmed Cell Death 1; PD-L1, Programmed Death Ligand; t; RT, Radiotherapy; cCRT, sequential CRT; ST, Systemic Therapy; SUR, Surgery; TKI, Tyrosine Kinase Inhibitors; VATS, Video-Assisted Thoracic Surgery.  
\end{table}